Abstract
Daily administration of LHRH analogues (agonists) has been documented to decrease biochemical findings and clinical signs of true precocious puberty. We have treated 10 girls, age 14 months to 9 years, with true idiopathic precocious puberty by intranasal inhalation of Nafarelin Acetate ([D-Nal(2)6]LHRH), 800-1500 μ g/day for 4 to 11 months. 9 girls showed decelerated growth velocity (from 9.7 ± .8 to 5.8 ± .8 cm/yr. p < 0.005, paired t test, n=8). 4 of these 9 girls were menstruating prior to therapy and all girls stopped menses subsequent to therapy. These 9 girls' estradiol levels also decreased significantly (from 46.3 ± 12.3 to 9.3 ± 1.8 pg/ml, p < 0.01, paired t test) as well as their 24 hour urinary LH levels (from 7.5 ± 1.8 to 2.7 ± 0.5 iu/day, p < 0.01, paired t test). The girl who did not respond to nasal inhalation therapy was administered subcutaneous injections of the same LHRH analogue. All children received intranasal inhalation without any observed side effects. These results suggest that most girls with true precocious puberty can be treated with intranasal administration of Nafarelin Acetate, a new LHRH analogue. (Supported in part by USPH Grant RR-00188 from the General Clinical Research Centers Branch, National Institutes of Health).
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lin, TH., Lepage, M., Henzl, M. et al. 179 INTRANASAL LHRH ANALOGUE TREATMENT OF IDIOPATHIC CENTRAL PRECOCIOUS PUBERTY IN GIRLS. Pediatr Res 19, 633 (1985). https://doi.org/10.1203/00006450-198506000-00199
Issue Date:
DOI: https://doi.org/10.1203/00006450-198506000-00199
This article is cited by
-
Long-term treatment of central precocious puberty with an intranasal LHRH analogue: control of pituitary function by urinary gonadotropins
European Journal of Pediatrics (1988)